Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Key Highlights
- ➤Relay Therapeutics (RLAY) management scheduled three November investor conference fireside chats
- ➤Zovegalisib is in Phase 3 ReDiscover-2 trial for HR+/HER2- metastatic breast cancer
- ➤Zovegalisib is being investigated for PI3Kα-driven vascular anomalies
- ➤Relay Therapeutics pipeline includes programs targeting NRAS-driven solid tumors and Fabry disease
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November: * Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 4:30 p.m. ET * UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 8:00 a.m. GMT / 3:00 a.m. ET * Jefferies Global Healthcare Conference on Wednesday, November 18, 2026 at 3:30 p.m. GMT / 10:30 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
Get started
Create a free account to read the full story.